Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to tame stubborn gout flares

NCT ID NCT05665699

Completed Disease control Sponsor: InventisBio Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether adding an investigational drug called D-0120 to the standard gout medication allopurinol can lower uric acid levels more effectively than allopurinol alone. The trial enrolls adults with gout who have had at least two flares in the past year and whose uric acid is not well controlled with current treatment. Participants receive D-0120 plus allopurinol for 12 weeks, and researchers measure changes in uric acid levels and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
D-0120 (an investigational drug) combined with allopurinol
What this could lead to
If successful, this combination could offer a more effective way to lower uric acid and reduce painful gout flares for people who don't respond well to standard therapy.
What could go wrong
This is an early-phase (phase II) trial with only 80 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to show meaningful benefit over existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gout

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GOUT

Contacts and locations

Locations

  • Site Center

    Plantation, Florida, 33324, United States

  • Site Center

    Louisville, Kentucky, 40205, United States

  • Site Center

    Hendersonville, Tennessee, 37075, United States

  • Site Center

    Fort Worth, Texas, 76109, United States

  • Site Center

    The Woodlands, Texas, 77382, United States

  • Site Center

    Richmond, Virginia, 23219, United States

  • Site Center

    Bellevue, Washington, 98004, United States

  • Study Center

    Birmingham, Alabama, 35233, United States

  • Study Center

    Evergreen Park, Illinois, 60805, United States

  • Study Center

    Brownsburg, Indiana, 46254, United States

  • Study Center

    Hickory, North Carolina, 28601, United States

  • Study Center

    Rocky Mount, North Carolina, 27804, United States

  • Study Center

    Salisbury, North Carolina, 28144, United States

  • Study Center

    Wilmington, North Carolina, 28401, United States

  • Study Center

    Winston-Salem, North Carolina, 27103, United States

  • Study Center

    Scottdale, Pennsylvania, 15683, United States

  • Study Center

    Bristol, Tennessee, 37620, United States

  • Study Center

    Knoxville, Tennessee, 37909, United States

  • Study Center

    Morgantown, West Virginia, 26505, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.